Abacus Medicine Pharmaceuticals ApS: Financial statements 2025
CVR: 39192063
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Abacus Medicine Pharmaceuticals ApS (CVR 39192063) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -80,000 and a net result of DKK -5,483,000 compared with DKK -2,436,000 the year before. Equity in the 2025 report amounted to DKK 14,264,000. The solvency ratio was 5.4%.
- Gross Profit
- DKK -80,000
- Profit/Loss
- DKK -5,483,000
- Equity
- DKK 14,264,000
- Total Assets
- DKK 261,896,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -80K | -5.5M | 14.3M | 0 |
| 2024 | - | -64K | -2.4M | 19.7M | 0 |
| 2023 | - | -73K | 1.4M | 22.2M | 0 |
| 2022 | - | -36K | -4.6M | 20.8M | 0 |
| 2021 | - | -43K | 2.8M | 25.4M | 0 |
Official annual report
How creditworthy is Abacus Medicine Pharmaceuticals ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
On November 7, 2025, the company changed its name from Abacus Medicine Pharma Services ApS to Abacus Medicine Pharmaceuticals ApS.
Abacus Medicine Pharmaceuticals ApS has published its annual report for 2024. Gross profit came to DKK -64,000, and the net result was DKK -2,436,000.
About Abacus Medicine Pharmaceuticals ApS
Abacus Medicine Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2017. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Abacus Medicine Pharma Services ApS and Aposave ApS. The management consists of Flemming Wagner. The company is owned by ABACUS MEDICINE A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -80,000 and a net result of DKK -5,483,000 compared with DKK -2,436,000 the year before. Equity in the 2025 report amounted to DKK 14,264,000.